5-苯基呋喃-2-基硼酸频哪醇酯 | 1396752-91-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-苯基呋喃-2-基硼酸频哪醇酯
• 英文名称: 5-phenylfuran-2-ylboronic acid pinacol ester
• 英文别名: 4,4,5,5-tetramethyl-2-(5-phenyl-2-furyl)-1,3,2-dioxaborolane；4,4,5,5-tetramethyl-2-(5-phenylfuran-2-yl)-1,3,2-dioxaborolane
• CAS: 1396752-91-2
• 化学式: C₁₆H₁₉BO₃
• 分子量: 270.136
• InChiKey: FSCIEWGQNCCYEQ-UHFFFAOYSA-N

物化性质

• 沸点：
  385.7±30.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.25
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  31.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-苯基呋喃-2-基硼酸频哪醇酯 在 吡啶 、 四(三苯基膦)钯 、 二异丙基铵盐四氮唑 作用下， 以 二氯甲烷 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.0h， 生成 3'-O-(P-2-cyanoethyl-N,N-diisopropylaminophosphinyl)-5'-O-(4,4′-dimethoxytrityl)-4-N-(N,N-dimethylaminomethylidenyl)-5-(5-phenylfuran-2-yl)-2'-deoxycytidine
  参考文献：
  名称：

  Increasing the Stability of DNA:RNA Duplexes by Introducing Stacking Phenyl-Substituted Pyrazole, Furan, and Triazole Moieties in the Major Groove

  摘要：

  Consecutive incorporations of our previously published thymidine analogue, 5-(1-pheny1-1H-1,2,3-triazol-4-yl)-2'-deoxyuridine monomer W in oligonudeotides, has demonstrated significant duplex-stabilizing properties due to its efficient staking properties in the major groove of DNA:RNA duplexes. The corresponding 2'-deoxycytidine analogue is not as well-accommodated in duplexes, however, due to its clear preference for the ring-flipped coplanar conformation. In our present work, we have used oh initio calculations to design two new building blocks, 5-(5-phenylfuran-2-yl)-2'-deoxycytidine monomer Y and 5-(1-phenyl-1H-pyrazol-3-yl)-2'-deoxycytidine monomer Z, that emulate the conformation of W. These monomers were synthesized by Suzuki-Miyaura couplings, and the pyrazole moiety was obtained in a cycloaddition from N-phenylsydnone. We show that the novel analogues Y and Z engage in efficient stacking either with themselves or with W due to a better overlap of the aromatic moieties. Importantly, we demonstrate that this translates into very thermally stable DNA:RNA duplexes, thus making Y and especially Z good candidates for improving the binding affinities of oligonudeotide-based therapeutics. Since we now have both efficiently stacking T and C analogues in hand, any purine rich stretch can be effectively targeted using these simple analogues. Notably, we show that the introduction of the aromatic rings in the major groove does not significantly change the helical geometry.

  DOI：

  10.1021/acs.joc.5b01577
• 作为产物：
  描述：

  溴苯 在 正丁基锂 、 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 为溶剂， 反应 0.5h， 生成 5-苯基呋喃-2-基硼酸频哪醇酯
  参考文献：
  名称：

  具有体内抗肿瘤功效的可逆DNA甲基转移酶和赖氨酸甲基转移酶G9a抑制剂的发现

  摘要：

  使用基于知识和结构的方法，我们设计并合成了可逆化学探针，该探针在纳摩尔范围内同时抑制两个表观遗传靶标（组蛋白3赖氨酸9甲基转移酶（G9a）和DNA甲基转移酶（DNMT））的活性。酶促竞争分析证实了我们的设计策略：底物竞争性抑制剂。接下来，围绕我们的第11个热门话题进行了初步探索，以找出用于体内测试的合适工具化合物。体外治疗不同的血液肿瘤细胞系可鉴定具有明确抗增殖作用的分子（GI 50值在纳摩尔范围内）。根据表观遗传功能性细胞反应（赖氨酸9甲基化和5-甲基胞嘧啶的水平），可接受的治疗窗（约1 log单位）和合适的药代动力学特征，选择12种用于体内概念验证（Nat。 COMMUN。 2017，8，15424）。在本文中，有12种获得了显着的体内功效：在小鼠模型中，人类急性髓样白血病（AML）异种移植物的总体肿瘤生长抑制率为70％。

  DOI：

  10.1021/acs.jmedchem.7b01926

文献信息

• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120232056A1

  公开（公告）日：2012-09-13

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的杂环化合物和组合物，并将其应用作药物治疗疾病。还提供了抑制人类或动物主体中PAS激酶（PASK）活性的方法，以治疗糖尿病等疾病。
• Substituted quinoxaline carboxylic acids for the inhibition of PASK
  申请人：McCall John M.

  公开号：US08912188B2

  公开（公告）日：2014-12-16

  Disclosed herein are substituted quinoxaline carboxylic acids of Formula (I): and compositions thereof, which may be useful as inhibitors of PAS Kinase (PASK) activity in a human or animal for the treatment of diseases such as diabetes mellitus.

  本文公开了式(I)的取代喹喔啉羧酸及其组合物，可能作为治疗糖尿病等疾病中人类或动物PAS激酶（PASK）活性抑制剂。
• [EN] HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR L'INHIBITION DE LA KINASE DE DOMAINE PAS (PASK)
  申请人：BIOENERGENIX

  公开号：WO2012119046A3

  公开（公告）日：2012-10-26
• Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy
  作者：Obdulia Rabal、Edurne San José-Enériz、Xabier Agirre、Juan Antonio Sánchez-Arias、Amaia Vilas-Zornoza、Ana Ugarte、Irene de Miguel、Estíbaliz Miranda、Leire Garate、Mario Fraga、Pablo Santamarina、Raul Fernandez Perez、Raquel Ordoñez、Elena Sáez、Sergio Roa、María José García-Barchino、José Angel Martínez-Climent、Yingying Liu、Wei Wu、Musheng Xu、Felipe Prosper、Julen Oyarzabal

  DOI：10.1021/acs.jmedchem.7b01926

  日期：2018.8.9

  reversible chemical probes that simultaneously inhibit the activity of two epigenetic targets, histone 3 lysine 9 methyltransferase (G9a) and DNA methyltransferases (DNMT), at nanomolar ranges. Enzymatic competition assays confirmed our design strategy: substrate competitive inhibitors. Next, an initial exploration around our hit 11 was pursued to identify an adequate tool compound for in vivo testing

  使用基于知识和结构的方法，我们设计并合成了可逆化学探针，该探针在纳摩尔范围内同时抑制两个表观遗传靶标（组蛋白3赖氨酸9甲基转移酶（G9a）和DNA甲基转移酶（DNMT））的活性。酶促竞争分析证实了我们的设计策略：底物竞争性抑制剂。接下来，围绕我们的第11个热门话题进行了初步探索，以找出用于体内测试的合适工具化合物。体外治疗不同的血液肿瘤细胞系可鉴定具有明确抗增殖作用的分子（GI 50值在纳摩尔范围内）。根据表观遗传功能性细胞反应（赖氨酸9甲基化和5-甲基胞嘧啶的水平），可接受的治疗窗（约1 log单位）和合适的药代动力学特征，选择12种用于体内概念验证（Nat。 COMMUN。 2017，8，15424）。在本文中，有12种获得了显着的体内功效：在小鼠模型中，人类急性髓样白血病（AML）异种移植物的总体肿瘤生长抑制率为70％。
• Increasing the Stability of DNA:RNA Duplexes by Introducing Stacking Phenyl-Substituted Pyrazole, Furan, and Triazole Moieties in the Major Groove
  作者：Mick Hornum、Pawan Kumar、Patricia Podsiadly、Poul Nielsen

  DOI：10.1021/acs.joc.5b01577

  日期：2015.10.2

  Consecutive incorporations of our previously published thymidine analogue, 5-(1-pheny1-1H-1,2,3-triazol-4-yl)-2'-deoxyuridine monomer W in oligonudeotides, has demonstrated significant duplex-stabilizing properties due to its efficient staking properties in the major groove of DNA:RNA duplexes. The corresponding 2'-deoxycytidine analogue is not as well-accommodated in duplexes, however, due to its clear preference for the ring-flipped coplanar conformation. In our present work, we have used oh initio calculations to design two new building blocks, 5-(5-phenylfuran-2-yl)-2'-deoxycytidine monomer Y and 5-(1-phenyl-1H-pyrazol-3-yl)-2'-deoxycytidine monomer Z, that emulate the conformation of W. These monomers were synthesized by Suzuki-Miyaura couplings, and the pyrazole moiety was obtained in a cycloaddition from N-phenylsydnone. We show that the novel analogues Y and Z engage in efficient stacking either with themselves or with W due to a better overlap of the aromatic moieties. Importantly, we demonstrate that this translates into very thermally stable DNA:RNA duplexes, thus making Y and especially Z good candidates for improving the binding affinities of oligonudeotide-based therapeutics. Since we now have both efficiently stacking T and C analogues in hand, any purine rich stretch can be effectively targeted using these simple analogues. Notably, we show that the introduction of the aromatic rings in the major groove does not significantly change the helical geometry.